April 19th 2024
Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.
FDA approves first once-daily eyedrop for inflammation and pain after cataract surgery
November 12th 2010Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
Read More
Increased cataracts risk in elderly associated with SSRIs, SNRIs
July 1st 2010In an on-line article published in the journal Ophthalmology, researchers reported a possible adverse association between certain selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) and the development of cataracts in those aged >65.
Read More
Travoprost: A prostaglandin analogue for the treatment of glaucoma
November 1st 2009In August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
Read More
Xalatan (latanoprost ophthalmic solution)
April 1st 2003FDA approval of this prescription eye drop makes it the first and only prostaglandin with a first-line indication for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Initially, latanoprost was only approved for second-line use.
Read More